Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

586 articles

Research Review

Showing 1–2 of 2 articles · Keyword: Exosomes Clear keyword

Discover nano2026ReviewNon-viral Gene DeliveryDrug Delivery

1. Exosomes in regenerative medicine from biological messengers to engineered nanocarriers for precision therapeutics

Ghosh S, Bhaskar R, Singh Kk, Sharma S, Han Ss, Sinha Jk

Exosomes have emerged as a promising class of next-generation nanocarriers at the intersection of regenerative medicine and drug delivery. Compared with conventional synthetic nanocarriers and stem cell-based therapies, exosomes offer unique advantages, including intrinsic biocompatibility, low immunogenicity…

Read the article

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026ReviewNon-viral Gene DeliveryDrug Delivery

2. miR-138-5p: From Multidimensional Tumor-Suppressive Regulatory Networks to Nanocarrier-Based Delivery for Solid Tumor Therapy

Leng T, Lv Y, Ha M, Zhu X, Jiang Y, Hu S, Et Al.

MicroRNA-138-5p (miR-138-5p) has been reported to exert tumor-suppressive effects in several solid tumors, and its downregulation has been associated with malignant progression, therapeutic resistance, and poor prognosis. This review summarizes research trends and current evidence on the molecular functions…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.